R. Schuck

发表

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

B. Dickerson, W. Marks, B. Boeve, 2019, Alzheimer's & Dementia.

Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting

I. Zineh, A. Terzic, Shiew-Mei Huang, 2021, Clinical pharmacology and therapeutics.

Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.

S. Poloyac, Craig R. Lee, A. Oni‐Orisan, 2012, American journal of physiology. Endocrinology and metabolism.

Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.

G. Stouffer, Craig R. Lee, Robert N. Schuck, 2018, Prostaglandins & other lipid mediators.

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers

I. Zineh, A. Shuldiner, R. Horenstein, 2014, Journal of clinical pharmacology.

Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity

K. Tomer, K. Hua, J. Falck, 2014, Journal of Lipid Research.

The Cytochrome P 450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease

K. Tomer, D. Zeldin, M. Edin, 2014 .

The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease

K. Tomer, D. Zeldin, M. Edin, 2014, PloS one.

Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice.

K. Tomer, Kimberly C. Molnar, D. Zeldin, 2013, Prostaglandins & other lipid mediators.

Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.

K. Tomer, G. Stouffer, D. Zeldin, 2012, Atherosclerosis.

Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice

K. Tomer, J. Foley, J. Falck, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease

I. Zineh, J. Woodcock, M. Pacanowski, 2017, Nature Reviews Drug Discovery.

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs

I. Zineh, R. Madabushi, M. Pacanowski, 2019, Clinical and translational science.

Integrative Aspects of Renal Endocrinology Enalapril reverses high-fat diet-induced alterations in cytochrome P 450-mediated eicosanoid metabolism

S. Poloyac, Craig R. Lee, A. Oni‐Orisan, 2012 .

Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop Proceedings.

Reena Philip, E. Litwack, G. Blumenthal, 2019, JCO precision oncology.

Biomarkers in drug development

J. Wagner, J. Delfino, Robert N. Schuck, 2022, Atkinson's Principles of Clinical Pharmacology.

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER : 206995 Orig 1 s 000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW ( S )

Yaning Wang, R. Schuck, 2022 .

Clinical and regulatory considerations in pharmacogenetic testing.

M. Pacanowski, Robert N. Schuck, R. Schuck, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

S. J. Schrieber, Chao Liu, Richard Pazdur, 2017, Clinical Cancer Research.

Translational Characterization of Arachidonic Acid Metabolism in Vascular Inflammation and Cardiovascular Disease

Robert N. Schuck, R. Schuck, 2013 .

An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials

I. Zineh, Jielin Sun, M. Pacanowski, 2019, Clinical pharmacology and therapeutics.

Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease.

J. Schisler, B. Jensen, Eleanor G. Hilliard, 2017, The American journal of pathology.

Beyond Statins: Lipid Management to Reduce Cardiovascular Risk

R. Simpson, Robert N. Schuck, P. Mendys, 2013, Pharmacotherapy.

Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease

I. Zineh, J. Woodcock, R. Charlab, 2018, Clinical pharmacology and therapeutics.

Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.

Norman Stockbridge, Rajanikanth Madabushi, Michael Pacanowski, 2015, Circulation.

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Jiang Liu, Xinyuan Zhang, Hao Zhu, 2022, Journal of clinical pharmacology.

Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans

D. Zeldin, N. Brown, Craig R. Lee, 2011, Hypertension.

Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.

K. Tomer, G. Stouffer, D. Zeldin, 2013, Atherosclerosis.

Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling

J. Grillo, Robert N. Schuck, R. Schuck, 2016, The AAPS Journal.

Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration

I. Zineh, G. Burckart, L. Yao, 2018, Clinical pharmacology and therapeutics.

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.